Posted by Michael Wonder on 26 Oct 2020
TLV is reconsidering the subsidy for hepatitis C drugs with side agreements
23 October 2020 - The current side agreements for hepatitis C drugs signed by the companies and the regions expire in full on 31 December 2020.
A dialogue is currently underway between the regions and the companies regarding the forthcoming contractual situation.
According to TLV, there is a reason to review whether the drugs included in the benefits have a reasonable cost and that the use of these hepatitis C drugs will thus meet the criteria in the Pharmaceutical Benefits Act after 31 December 2020.
